Question

What what will happen in 12 months to a patient 71 years old with an Aveir VR, a single-chamber ventricular leadless pacemaker that does not sense or pace the atrium, so it cannot actively preserve AV synchrony?

Answer

Over a 12‑month horizon, most patients with an Aveir VR (VVI/VVI‑R leadless pacemaker) experience a stable device course with routine follow‑up. What changes—and what matters—tends to fall into four buckets: device metrics, symptoms, activity/fitness, and programming strategy. Because a single‑chamber system cannot maintain AV synchrony, a minority of patients can develop or continue to have pacemaker syndrome–type symptoms, especially when the ventricular pacing percentage (VP%) is high and retrograde VA conduction is present. The outline below summarizes typical expectations; individual care must be guided by an electrophysiologist.

1) Device metrics (typical trends)

Capture threshold & sensing: Often settle within weeks after implant and remain stable through 12 months; small drifts can occur.
Impedance: May rise modestly over the first months as the leadless electrode–tissue interface matures, then plateau.
Battery estimate: Should remain far from end‑of‑service at 12 months in usual programming; longevity depends mainly on VP% and output settings.
VP%: Varies by underlying rhythm; higher VP% increases the chance of AV dyssynchrony symptoms.

2) Symptoms (what to watch)

Well‑tolerated in many: No specific symptoms beyond expected recovery and routine aging.
Possible AV‑dyssynchrony features: Fatigue, light‑headedness, exercise intolerance, neck pounding (cannon A‑waves), or a vague chest/neck “discomfort”—often worse when VP% is high, after meals, or with posture changes.
Red flags: Syncope/near‑syncope, resting dyspnea, chest pain, confusion, or new edema warrant urgent evaluation.

3) Activity & fitness

Most patients resume or maintain age‑appropriate activity. Objective checks (e.g., 6‑minute walk test or steady‑state treadmill/ergometer) can document functional capacity.
If rate‑response is too brisk or too insensitive, patients may notice reduced exercise comfort; tuning these settings can help.

4) Programming strategy (to minimize VP% & symptoms)

Favor intrinsic conduction when safe: Use lower base rate and enable/extend ventricular hysteresis (when available).
Tame rate‑response: Calibrate sensitivity/slope and activity threshold to avoid unnecessary pacing at rest or mild activity.
Manage retrograde VA conduction: In select cases, AV‑nodal blockers can reduce symptoms driven by VA conduction.
Escalation path: If symptoms persist and are clearly pacing‑related, discuss dual‑chamber options or alternative system strategies with EP.

Typical follow‑up cadence through 12 months

Early checks: Post‑implant and at ~1–3 months to confirm stable thresholds/sensing and tune programming.
Ongoing: Remote monitoring plus an in‑clinic visit around 6–12 months, or sooner if symptoms change.
Testing when indicated: Surface ECG or ambulatory patch during symptoms; echocardiography if heart failure signs, valve issues, or reduced exercise tolerance emerge.

What generally does not change in 12 months

The device remains single‑chamber and cannot create AV synchrony; symptom risk therefore depends on individual conduction physiology and VP% rather than “time since implant.”
Battery depletion to end‑of‑service within 12 months is uncommon unless very high outputs/VP% are required.

Important: This is educational, not medical advice. Outcomes vary by underlying conduction disease, comorbidities, medications, and device programming. If symptoms suggest pacemaker syndrome or change over time, contact your electrophysiology team for individualized evaluation.